In this activity, two leading experts in multiple myeloma provide the latest updates in novel treatment regimens used in practice today and review emerging regimens currently in clinical trials for potential use in the future. They discuss how to currently approach treatment decisions for your patients with newly diagnosed multiple myeloma (NDMM) and strategies that may be incorporated into treatment to impact patient quality of life.

This activity was previously presented as a live webinar. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.